Jan-14-21 Downgrade
Citigroup
Buy → Neutral
$14
Oct-29-20 Upgrade
Citigroup
Neutral → Buy
$14
Jun-09-20 Downgrade
Citigroup
Buy → Neutral
$14
Mar-16-20 Downgrade
Oppenheimer
Perform → Underperform
Mar-12-20 Upgrade
Citigroup
Neutral → Buy
$14
Nov-07-19 Downgrade
Citigroup
Buy → Neutral
$19
Aug-01-19 Upgrade
Citigroup
Neutral → Buy
$19
Jul-25-19 Downgrade
Stifel
Buy → Hold
$26 → $17
Dec-11-18 Downgrade
Oppenheimer
Outperform → Perform
Dec-04-18 Upgrade
Cantor Fitzgerald
Neutral → Overweight
Dec-04-18 Reiterated
Jefferies
Buy
$30 → $40
Nov-08-18 Resumed
Jefferies
Buy
Sep-21-18 Resumed
Oppenheimer
Outperform
May-23-18 Initiated
Citigroup
Buy
$26
Jan-19-18 Initiated
Seaport Global Securities
Buy
$20
Sep-14-17 Reiterated
Piper Jaffray
Overweight
$23 → $26
Jun-27-17 Resumed
Piper Jaffray
Overweight
$23
May-26-17 Initiated
H.C. Wainwright
Buy
$18
Apr-12-17 Initiated
Oppenheimer
Outperform
$21
Nov-09-16 Initiated
Aegis Capital
Buy
$24
Dec-19-20 06:11PM
Dec-02-20 03:02PM
07:35AM
Dec-01-20 06:00PM
04:47AM
Nov-17-20 12:43PM
Oct-29-20 09:31AM
Oct-28-20 05:55PM
04:01PM
02:30PM
Oct-26-20 04:01PM
Oct-21-20 04:45PM
Oct-13-20 01:14PM
Oct-02-20 01:44PM
Sep-15-20 03:41PM
Aug-31-20 06:30PM
Aug-18-20 10:24AM
07:00AM
Aug-06-20 08:21PM
Aug-05-20 06:05PM
04:01PM
Aug-03-20 08:53AM
07:00AM
Jul-29-20 05:00PM
Jul-22-20 12:32PM
Jul-21-20 04:04PM
Jul-14-20 11:02AM
08:04AM
Jul-13-20 04:30PM
Jun-19-20 02:38PM
May-26-20 07:00AM
May-21-20 05:08PM
May-20-20 05:20PM
10:45AM
May-15-20 11:43AM
May-14-20 07:03AM
May-13-20 07:00AM
May-08-20 07:32PM Thomson Reuters StreetEvents
May-07-20 11:31AM
May-06-20 06:45PM
Apr-29-20 04:05PM
12:34PM
Apr-27-20 02:18PM
Apr-23-20 09:12AM American City Business Journals
Apr-22-20 01:01PM
Apr-21-20 05:14PM
Apr-17-20 10:00AM
08:54AM American City Business Journals
Apr-16-20 10:58AM
08:09AM
Apr-15-20 04:15PM
04:05PM
Apr-09-20 07:52AM
Apr-08-20 04:05PM
Apr-03-20 02:26PM American City Business Journals -6.81%
Apr-02-20 01:36PM
Mar-19-20 12:59PM American City Business Journals +9.47%
Mar-10-20 05:13PM Thomson Reuters StreetEvents +8.69%
Feb-27-20 05:35PM
Feb-26-20 03:05PM American City Business Journals
Feb-25-20 04:13PM
04:01PM
Feb-21-20 12:26PM
Feb-19-20 07:00AM
Feb-18-20 08:22PM
Feb-05-20 09:15AM
Feb-03-20 03:28PM American City Business Journals
Jan-31-20 06:24PM
Jan-16-20 02:57PM American City Business Journals
Jan-13-20 02:11PM
Jan-12-20 03:34PM
Dec-29-19 09:40PM
Dec-23-19 02:27PM
Dec-12-19 05:15PM
Dec-10-19 09:12PM
Nov-19-19 07:15AM Thomson Reuters StreetEvents
Nov-18-19 04:01PM
10:04AM
Nov-14-19 10:35AM
Nov-07-19 07:18AM
Nov-06-19 04:01PM
Oct-31-19 01:25PM
Oct-30-19 04:30PM
10:33AM
Oct-28-19 04:30PM
Oct-23-19 04:01PM
Oct-16-19 04:01PM
Oct-15-19 08:25AM
Oct-10-19 01:49PM
Sep-25-19 06:18PM
Sep-11-19 05:20PM
Sep-04-19 10:55AM
Aug-28-19 08:02AM
Aug-21-19 11:00AM
07:00AM
Aug-20-19 08:34AM
Aug-19-19 02:54PM American City Business Journals
10:06AM
07:00AM
Aug-13-19 03:23PM
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Polymeropoulos Mihael Hristos President and CEO Dec 15 Option Exercise 8.75 46,663 408,301 1,342,897 Dec 15 04:24 PM Polymeropoulos Mihael Hristos President and CEO Dec 15 Sale 13.00 39,150 508,844 1,303,747 Dec 15 04:24 PM Polymeropoulos Mihael Hristos President and CEO Dec 14 Option Exercise 8.75 61,520 538,300 1,347,283 Dec 15 04:24 PM Polymeropoulos Mihael Hristos President and CEO Dec 14 Sale 13.19 51,049 673,306 1,296,234 Dec 15 04:24 PM Polymeropoulos Mihael Hristos President and CEO Dec 11 Option Exercise 8.75 41,817 365,899 1,320,816 Dec 15 04:24 PM Polymeropoulos Mihael Hristos President and CEO Dec 11 Sale 12.88 35,053 451,360 1,285,763 Dec 15 04:24 PM Wijkstrom Joakim SVP, Chief Marketing Officer Aug 20 Sale 11.08 3,710 41,109 56,290 Aug 21 06:08 PM Williams Timothy SVP & General Counsel Aug 14 Sale 11.81 3,684 43,526 79,356 Aug 17 04:42 PM Jones Aranthan II Chief Corp. Affairs Officer Aug 12 Sale 11.81 7,200 85,018 75,487 Aug 14 04:39 PM Jones Aranthan II Chief Corp. Affairs Officer Jul 27 Sale 10.62 7,313 77,631 82,687 Jul 29 08:17 PM Watkins Thomas Director May 29 Option Exercise 7.38 15,000 110,700 45,000 Jun 02 04:13 PM Watkins Thomas Director May 29 Sale 11.50 9,677 111,286 35,323 Jun 02 04:13 PM DUGAN RICHARD W Director May 28 Option Exercise 7.38 15,000 110,700 50,770 May 29 04:10 PM DUGAN RICHARD W Director May 28 Sale 11.04 10,129 111,806 40,641 May 29 04:10 PM Williams Timothy SVP & General Counsel Mar 03 Sale 10.51 1,237 13,004 83,040 Mar 04 05:03 PM Polymeropoulos Mihael Hristos President and CEO Mar 03 Sale 10.98 5,152 56,544 1,278,999 Mar 04 05:02 PM Birznieks Gunther SVP, Business Development Mar 03 Sale 10.66 5,535 58,984 159,473 Mar 04 05:00 PM Kelly James Patrick EVP & Chief Financial Officer Mar 03 Sale 10.76 5,889 63,359 186,869 Mar 04 05:01 PM Reverberi Gian Piero SVP & Chief Commercial Officer Mar 02 Sale 10.18 1,450 14,755 165,384 Mar 04 05:02 PM Williams Timothy SVP & General Counsel Mar 02 Sale 10.30 3,148 32,436 84,277 Mar 04 05:03 PM Polymeropoulos Mihael Hristos President and CEO Mar 02 Sale 10.57 10,428 110,211 1,284,151 Mar 04 05:02 PM Birznieks Gunther SVP, Business Development Mar 02 Sale 10.04 12,223 122,686 165,008 Mar 04 05:00 PM Kelly James Patrick EVP & Chief Financial Officer Mar 02 Sale 10.19 12,968 132,087 192,758 Mar 04 05:01 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite